CTLA4 and melanoma: These drugs have 40–60% response rates when used as monotherapies, with many of those responses lasting a long time [209].b)CTLA-4 Inhibitors: Ipilimumab is a CTLA-4 inhibitor used in advanced melanoma treatment.